Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
TruScreen Group Ltd. ( (AU:TRU) ) has issued an announcement.
TruScreen Group Limited announced the peer-reviewed publication of a Saudi Arabian study in BMC Women’s Health, confirming the high sensitivity and specificity of its TruScreen device compared to traditional pap smears for cervical cancer detection. The study, which tested 507 women, highlighted TruScreen’s potential as a practical screening tool that does not require cervical samples or specialized personnel, offering an evidence-based approach for countries lacking national screening programs.
More about TruScreen Group Ltd.
TruScreen Group Limited is a medical device company that has developed an AI-enabled device for real-time detection of cervical tissue abnormalities. Their technology facilitates cervical screening without the need for biological tissue sampling, reducing discomfort and the necessity for specialized personnel and laboratory infrastructure. The TruScreen Ultra device is registered and approved for use in multiple countries and has been integrated into cervical cancer screening guidelines in China.
YTD Price Performance: 45.00%
Average Trading Volume: 186,655
Technical Sentiment Signal: Sell
Current Market Cap: A$15.45M
See more data about TRU stock on TipRanks’ Stock Analysis page.